Prenylated chalcone analog-mediated Inhibition of Toxoplasma gondii growth in human trophoblast cell line and villous explants
- PMID: 40604186
- PMCID: PMC12223089
- DOI: 10.1038/s41598-025-08764-y
Prenylated chalcone analog-mediated Inhibition of Toxoplasma gondii growth in human trophoblast cell line and villous explants
Abstract
Congenital toxoplasmosis is a significant public health issue caused by the transplacental passage of Toxoplasma gondii to the embryo/fetus. The standard treatment involves a combination of sulfadiazine and pyrimethamine, drugs often associated with adverse effects and high toxicity. The current study aimed to investigate the potential of prenylated chalcones (C2, C4 and C9) in controlling T. gondii infection in human trophoblast cells (BeWo) and human placental explants. As results, non-cytotoxic doses of C2, C4 and C9 impaired parasite invasion and subsequent intracellular proliferation in BeWo cells. Scanning and transmission electron microscopies evidenced the direct effect of chalcones on tachyzoites, which presented irregular rough surface, membrane with hole-like structures, torsion and shape substantial changes after pretreatment. C4 and, especially C9, caused notable ultrastructural damages due to the formation of vacuole-like structures in the parasite cytoplasm and surrounding the parasitophorous vacuole. Additionally, chalcones modulated the cytokine profile by increasing IL-8 and downmodulating MIF and ROS levels in BeWo cells and downregulating TNF-α release in villous explants. These findings highlight C2, C4, and C9 as promising candidates for the development of alternative therapies to prevent congenital toxoplasmosis, as well as chalcones as a valuable scaffold for the design of new anti-T. gondii agents.
Keywords: Toxoplasma gondii; Chalcones; Flavonoid; Placenta; Treatment; Trophoblast.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests and no competing financial interests.
Figures









Similar articles
-
Enrofloxacin and Toltrazuril Are Able to Reduce Toxoplasma gondii Growth in Human BeWo Trophoblastic Cells and Villous Explants from Human Third Trimester Pregnancy.Front Cell Infect Microbiol. 2017 Jul 26;7:340. doi: 10.3389/fcimb.2017.00340. eCollection 2017. Front Cell Infect Microbiol. 2017. PMID: 28798905 Free PMC article.
-
In vitro and in vivo activity of quisinostat against Toxoplasma gondii.Antimicrob Agents Chemother. 2025 Sep 3;69(9):e0181924. doi: 10.1128/aac.01819-24. Epub 2025 Jul 31. Antimicrob Agents Chemother. 2025. PMID: 40741955 Free PMC article.
-
Furan derivative affects the cell division and mitochondrial integrity of tachyzoites of Toxoplasma gondii.Exp Parasitol. 2025 Aug;275:108988. doi: 10.1016/j.exppara.2025.108988. Epub 2025 Jul 8. Exp Parasitol. 2025. PMID: 40639481
-
Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review.Parasitol Res. 2018 Oct;117(10):3045-3057. doi: 10.1007/s00436-018-6027-z. Epub 2018 Aug 8. Parasitol Res. 2018. PMID: 30088074
-
Prevalence of Toxoplasma gondii infection in animals of the Arabian Peninsula between 2000-2020: A systematic review and meta-analysis.Vet Med Sci. 2023 Jan;9(1):471-480. doi: 10.1002/vms3.1004. Epub 2022 Nov 21. Vet Med Sci. 2023. PMID: 36408778 Free PMC article.
References
-
- Dubey, J. P., Lago, E. G., Gennari, S. M., Su, C. & Jones, J. L. Toxoplasmosis in humans and animals in brazil: High prevalence, high burden of disease, and epidemiology. Parasitology139, 1375–1424. 10.1017/s0031182012000765 (2012). - PubMed
-
- Montoya, J. G., Liesenfeld, O. & Toxoplasmosis Lancet 363, 1965– (1976). 10.1016/s0140-6736(04)16412-x (2004). - PubMed
-
- Ahmed, M., Sood, A. & Gupta, J. Toxoplasmosis in pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol.255, 44–50. 10.1016/j.ejogrb.2020.10.003 (2020). - PubMed
-
- Kodjikian, L. et al. Vertical transmission of toxoplasmosis from a chronically infected immunocompetent woman. Pediatr. Infect. Dis. J.23, 272–274. 10.1097/01.inf.0000115949.12206.69 (2004). - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous